Brief: Santhera Gets Positive CHMP Opinion To Expand Agamree (Vamorolone) Use
27/04/2026 06:03
April 27 (Reuters) - Santhera Pharmaceuticals Holding AG SANN.S: SANTHERA RECEIVES POSITIVE CHMP OPINION TO EXPAND AGAMREE® (VAMOROLONE) USE IN PEDIATRIC DMD PATIENTS AGED TWO AND OLDER IN THE EU Source text: ID:nGNEjpgb1 Further company coverage: SANN.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Santhera Pharmaceuticals Holding AG
See all newsSwitzerland's Santhera Pharma H1 revenue soars on AGAMREE sales, milestones
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -6.562 Million
Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
Brief: Santhera Gets Positive CHMP Opinion To Expand Agamree (Vamorolone) Use
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -35.444 Million